Medco's Personalized Medicine Focus Includes SureGene Dx Development
This article was originally published in The Gray Sheet
Executive Summary
Medco will launch a research project in November in collaboration with genetic test developer SureGene to validate a biomarker that may improve the cost effectiveness of atypical antipsychotic drug treatment. The SureGene pact was announced Aug. 24